Aesthetics

Safety, Tolerability, and Efficacy of Repeat-Dose Injections of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results from a Prospective, Open-Label, Phase III Study

By April 29, 2020No Comments

Dermatology News

"Safety, Tolerability, and Efficacy of Repeat-Dose Injections of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results from a Prospective, Open-Label, Phase III Study"

IncobotulinumtoxinA (Xeomin/Xeomeen/Bocouture/XEOMIN Cosmetic; botulinum toxin type A free from complexing proteins [150 kDa]; Merz Pharmaceuticals GmbH) is indicated worldwide for the correction of glabellar frown lines (GFL) and in Europe additionally for lateral periorbital lines (LPL; crow’s feet) and upper facial lines (UFL; ie, simultaneous treatment of GFL, LPL, and horizontal forehead lines [HFL]).1

The efficacy of incobotulinumtoxinA in the treatment of multiple or singular facial areas has been extensively demonstrated.2-10 With the recent surge in interest for a more holistic approach, consisting of combined treatment of GFL, HFL, and LPL in a single treatment session, there is a need for demonstrating safety and efficacy for such procedures.

This study provides strong evidence for the safety and tolerability of repeat-dose treatments with incobotulinumtoxinA in UFL (GFL, 20 U; HFL, 10-20 U; LPL, 24 U). A stable safety profile was demonstrated during prolonged administration and a noteworthy trend to better tolerability with continued use of incobotulinumtoxinA was established

Read More

You May Also Like

New Innovations with SkinCeuticals Advanced RGN-6

| JDD Highlights, JDD Webinars, The Latest | No Comments
Active ingredients play a critical role in the efficacy and safety of cosmeceuticals. Join Dr. Corey L. Hartman, as he shares information on a new cosmeceutical formulation. This presentation will…

Dermatology Roundup: Dermatologist Joins Investigators at Chan Zuckerberg Biohub New York

| JDD Highlights, JDD in the Media, The Latest | No Comments
By Allison Sit Dermatologist Aimee Payne, MD, PhD, is part of the second cohort of investigators with the Chan Zuckerberg Biohub New York, a research institute that is focused on harnessing…
Journal of Drugs in Dermatology JDD About Cancer Prevention Month. Image from the Full Spectrum of Dermatology: A Diverse and Inclusive Atlas of a darker skin tone nose or face with a pigmented basal cell carcinoma.

February: National Cancer Prevention Month

| JDD Highlights, Latest News, Skin Cancer, The Latest | No Comments
A Spotlight on Skin Health As February unfolds, so does an important reminder—this month is National Cancer Prevention Month. For dermatologists, it's a time to reinforce awareness, education, and proactive…

Leave a Reply